^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:entospletinib (GS-9973) (SYK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Haematologica
    Title:

    Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia

    Published date:
    05/15/2020
    Excerpt:
    ...entospletinib did not decrease leukemia burden in two KMT2A-AFF1 PDX models with NRAS/ or KRAS mutations, suggesting potential RAS-mediated resistance to SYK inhibition.
    DOI:
    10.3324/haematol.2019.241729